Viva Biotech logo

Viva Biotech(SEHK) 1873

Market CapHK$2.83BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-69%
5 Year-78%
1 Year-47%
1 Month+5%
HK$1.33
-3.28%
-0.04Today
Viva Biotech last closing stock price
MetricPriceDate
Last closeHKD 1.372026-10-14
Viva Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-18.93%HKD 1.692026-10-07
1 month+4.58%HKD 1.312026-09-14
3 month+3.79%HKD 1.322026-07-16
Year to date-23.89%HKD 1.802025-12-31
1 year-46.69%HKD 2.572025-10-14
3 year-0.72%HKD 1.382023-10-13
5 year-77.87%HKD 6.192021-10-15
Since inception-68.58%HKD 4.392019-05-09

Viva Biotech Financials at a Glance

Market Cap

HK$2.83BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥3.73B

Net Income (TTM)

CN¥349.22M

EPS (TTM)

HK$0.09

P/E Ratio

14.54

Dividend

HK$0.00

Beta (Volatility)

0.06 (Low)

Price

HK$1.33

Volume

4,230,500

Open

HK$1.37

Previous Close

HK$1.37

Daily Range

HK$1.32 - HK$1.37

52-Week Range

HK$1.04 - HK$2.86

Estimated Earnings Date

Apr 1, 2027

1873 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Viva Biotech

Viva Biotech Holdings, founded in 2008 and based in Shanghai, China, specializes in providing comprehensive, structure-based drug discovery services to biotechnology and pharmaceutical clients globally. The company offers a wide range of services, including discovery biology, chemistry, and antibody drug research and development.

Products and Services
  • Discovery biology services, including protein expression and purification
  • Chemistry services, such as medicinal and synthetic chemistry
  • Antibody drug research, covering multi-species antibody discovery
Growth Outlook
  • Revenue increased to CNY 992.6 million in Q2 2026, up from CNY 897.6 million in Q4 2025
  • Net income rose to CNY 78.97 million in Q2 2026, reflecting strong operational performance
  • Operating income margin improved to 11.34% in Q2 2026, indicating enhanced efficiency
Financial Highlights
  • Trailing twelve-month revenue of CNY 3.5 billion, showcasing consistent growth
  • Net profit margin of 9.36% for the trailing twelve months, indicating profitability
  • Current ratio of 1.52, reflecting strong liquidity position
Viva Biotech Holdings operates in the biotechnology sector, focusing on drug discovery and development services. The company has demonstrated significant growth in revenue and net income, particularly in the most recent quarter, which may attract potential investors. The improvement in operating income margin suggests that the company is becoming more efficient in its operations. With a solid financial position, as indicated by the current ratio, Viva Biotech is well-positioned to capitalize on future opportunities in the biotechnology industry.
AI Generated • Oct 13, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

2,169

CEO

Chen Mao

Website

www.vivabiotech.com

Headquarters

Shanghai, SH 201318, CN

1873 Financials

Key Financial Metrics (TTM)

Gross Margin

34.55%

Operating Margin

10.05%

Net Income Margin

9.36%

Return on Equity

4.45%

Return on Capital

3.63%

Return on Assets

2.57%

Earnings Yield

6.88%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

HK$2.83BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.07B

Volume

4.23M

Avg. Volume

6.03M

Financials (TTM)

Gross Profit

CN¥1.34B

Operating Income

CN¥413.93M

EBITDA

CN¥839.52M

Operating Cash Flow

CN¥778.84M

Capital Expenditure

-CN¥279.90M

Free Cash Flow

CN¥498.94M

Cash & ST Invst.

CN¥1.06B

Total Debt

CN¥897.96M

Viva Biotech Performance Analysis

Viva Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 2,767,221,0099.1%
20232023-12-31CNY 2,381,909,373-13.9%
20242024-12-31CNY 2,153,974,381-9.6%
20252025-12-31CNY 1,875,624,605-12.9%
Viva Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-312.3%
Q22025-06-30-17.2%
Q42025-12-317.9%
Q22026-06-3010.6%
Viva Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -0.32N/A
20232023-12-31CNY -0.16-50.7%
20242024-12-31CNY 0.06N/A
20252025-12-31CNY 0.1061.2%
Viva Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-66.8%
Q22025-06-30176.2%
Q42025-12-31-10.8%
Q22026-06-30-24.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥992.63M

+1.1%

Gross Profit

CN¥337.01M

-0.6%

Gross Margin

33.95%

N/A

Market Cap

HK$2.83BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$1.28M

N/A

Employees

2,213

N/A

Net Income

CN¥78.97M

-32.4%

EBITDA

CN¥211.59M

-3.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥1.06B

+2.0%

Total Debt

CN¥897.96M

-41.7%

Accounts Receivable

CN¥254.99M

-42.9%

Inventory

CN¥398.62M

+76.8%

Long Term Debt

CN¥299.51M

-66.3%

Short Term Debt

CN¥598.45M

-8.4%

Return on Assets

2.57%

N/A

Return on Invested Capital

3.33%

N/A

Free Cash Flow

CN¥239.63M

+899.4%

Operating Cash Flow

CN¥335.15M

+120.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,709.28-0.01%
^DJIDJI
$51,466.30-0.00%
^IXICNASDAQ
$26,684.28-0.02%
BTCBitcoin
$81,564.00-0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$110.54-13.35%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$42.52+13.63%
TQQQProShares Trust - ProShares UltraPro Qqq
$74.12-5.95%
NOKNokia
$9.40-4.67%

Questions About 1873

What is the current price of Viva Biotech?

Viva Biotech is trading at HK$1.33 per share.

What is the 52-week range for Viva Biotech?

Over the past 52 weeks, Viva Biotech has traded between HK$1.04 and HK$2.86.

How much debt does Viva Biotech have?

As of the most recent reporting period, Viva Biotech reported total debt of CN¥1.48B.

How much cash does Viva Biotech have on hand?

Viva Biotech reported CN¥1.21B in cash and cash equivalents in its most recent financial results.

What is Viva Biotech’s dividend yield?

Viva Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services